Racial differences in PSA screening interval and stage at diagnosis

Cancer Causes and Control

Volumn 21, Issue 7, 2010, Pages 1071-1080

  Carpenter, William R ^a,b,c,d   Howard, Daniel L ^d   Taylor, Yhenneko J ^d   Ross, Louie E ^d   Wobker, Sara E ^b   Godley, Paul A ^a,b,e  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c North Carolina Comprehensive Cancer Program   (United States)

^d SHAW UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Early detection of cancer; Health care disparities; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CAUCASIAN; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RISK ASSESSMENT; RISK REDUCTION;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; MEDICARE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM; TIME FACTORS; UNITED STATES;

EID: 77955665306     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-010-9535-4     Document Type: Article

References (42)

1. American Cancer Society (2009) Cancer facts & figures 2009. American Cancer Society, Atlanta
2. American Cancer Society (2009) Cancer facts and figures for African Americans, 2009-2010 American Cancer Society, Atlanta
3. Institute of Medicine (2003) Unequal treatment: confronting racial and ethnic disparities in healthcare. National Academies Press, Washington DC
4. Institute of Medicine (1999) The unequal burden of cancer: as assessment of NIH research and programs for ethnic minorities and the medically underserved. National Academies Press, Washington DC
5. Bach PB, Cramer LD, Warren JL, Begg CB (1999) Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341(16):1198-1205
6. Field TS, Buist DS, Doubeni C et al. (2005) Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr (35):88-95
7. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B (1995) Geographic, age, and racial variation in the treatment of local/ regional carcinoma of the prostate. J Clin Oncol 13(1):93-100
8. Gilligan T, Wang PS, Levin R, Kantoff PW, Avorn J (2004) Racial differences in screening for prostate cancer in the elderly. Arch Intern Med 164(17):1858-1864
9. Giovannucci E, Stampfer MJ, Krithivas K et al (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94(7):3320-3323
10. Hayes RB, Ziegler RG, Gridley G et al (1999) Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 8(1):25-34
11. Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78-85
12. Moul JW, Sesterhenn IA, Connelly RR et al (1995) Prostatespecific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 274(16):1277-1281
13. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO (1997) Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277(6):467-471
14. Jonsson E, Sigbjarnarson HP, Tomasson J et al (2006) Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Scand J Urol Nephrol 40(4):265-271
15. Tabar L, Fagerberg CJ, Gad A et al (1985) Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the breast cancer screening working group of the Swedish national board of health and welfare. Lancet 1(8433):829-832
16. Mandel JS, Bond JH, Church TR et al (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328(19):1365-1371
17. Laara E, Day NE, Hakama M (1987) Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1(8544):1247-1249
18. Amling CL (2006) Prostate-specific antigen and detection of prostate cancer: what have we learned and what should we recommend for screening? Curr Treat Options Oncol 7(5):337-345
19. Agalliu I, Weiss NS, Lin DW, Stanford JL (2007) Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Cancer Causes Control 18(9):931-937
20. Weinmann S, Richert-Boe K, Glass AG, Weiss NS (2004) Prostate cancer screening and mortality: a case-control study (United States). Cancer Causes Control 15(2):133-138
21. Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G (2006) Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 164(4):376-384
22. Andriole GL, Crawford ED, Grubb RL III et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-1319
23. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320-1328
24. Smith DS, Catalona WJ, Herschman JD (1996) Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 276(16):1309-1315
25. Gilliland FD, Hunt WC, Key CR (1996) Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen era. Urology 48(1):67-71
26. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG (2004) Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 100(7):1397-1405
27. Ung JO, Richie JP, Chen MH, Renshaw AA, D′Amico AV (2002) Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60(3):458-463
28. Virnig BA, Baxter NN, Habermann EB, Feldman RD, Bradley CJ (2009) A matter of race: early-versus late-stage cancer diagnosis. Health Aff (Millwood) 28(1):160-168
29. Hugosson J, Aus G, Bergdahl S et al (2003) Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 92(Suppl 2):39-43
30. Kundu SD, Grubb RL, Roehl KA, Antenor JA, Han M, Catalona WJ (2005) Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol 173(4):1116-1120
31. Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:3-18
32. Fritz A, Ries L (eds) (1998) The SEER program code manual, 3rd edn. National Cancer Institute, Bethesda, MD
33. Yao SL, Lu-Yao G (2001) Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer. J Urol 166:861-865
34. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J.Clin Epidemiol 53:1258-1267
35. Barry MJ (2009) Screening for prostate cancer-the controversy that refuses to die. NEJM 360(13):1351-1354
36. Zoorob R, Anderson R, Cefalu C, Sidani M (2001) Cancer screening guidelines. Am Fam Physician 63(6):1101-1112
37. Carpenter WR, Godley PA, Finnegan T, Talcott JA, Clark JA, Mishel M, Schroeder JC, Bensen JT, Su JL, Fontham ETH, Mohler JL (2009) Racial differences in the roles of trust, regular source of patient care, and screening and treatment utilization among individuals with prostate cancer. Cancer 155(21):5048-5059
38. Talcott JA, Spain P, Clark JA, Carpenter WR, Do YK, Hamilton RJ, Galanko JA, Jackman A, Godley PA (2007) Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer 109(8):1599-1606
39. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest oncology group. JNCI 101(14):984-992
40. Lacher DA, Thompson TD, Hughes JP, Saraiya M (2006) Total, free, and percent free prostate-specific antigen levels among US men, 2001-04. Adv Data 379:1-12
41. Efstathiou JA, Chen MH, Catalona WJ et al (2006) Prostatespecific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology 68(2):342-347
42. Ulmert D, Cronin AM, Bjork T et al (2008) Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 6:6